Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Alternative Names: PMN-310; TDP 43 targeting therapeutics

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein modulators; Superoxide dismutase inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis
  • Research Down syndrome

Most Recent Events

  • 30 Mar 2017 ProMIS Neurosciences announces intention to submit IND application in late 2018
  • 05 Jan 2017 Preclinical trials in Alzheimer's disease in Canada before January 2017 (Parenteral)
  • 08 Oct 2016 ProMIS Neurosciences expands exclusive license agreement with the University of British Columbia to gain worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications and enhancements to ProMIS™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top